IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 170, Issue 9, 2003, Pages 4776-4784

  Teige, Ingrid ^a   Treschow, Alexandra ^a   Teige, Anna ^a   Mattsson, Ragnar ^a   Navikas, Vaidrius ^a   Leanderson, Tomas ^a   Holmdahl, Rikard ^a   Issazadeh Navikas, Shohreh ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 4;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFER; CENTRAL NERVOUS SYSTEM; CHRONICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE SEVERITY; EFFECTOR CELL; FEMALE; GENE DELETION; GENE DISRUPTION; HISTOPATHOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MALE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE INJURY;

EID: 0037407587     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.9.4776     Document Type: Article

References (53)

1. Pestka, S., J. A. Langer, K. C. Zoon, and C. E. Samuel. 1987. Interferons and their actions. Annu. Rev. Biochem. 56:727.
2. Sun, S., X. Zhang, D. F. Tough, and J. Sprent. 1998. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188:2335.
3. + dendritic cells to produce type I IFN. J. Immunol. 166:2291.
4. Abdul-Ahad, A. K., A. R. Galazka, M. Revel, M. Biffoni, and E. C. Borden. 1997. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells. Cytokines Cell. Mol. Ther. 3:27.
5. Hafler, D. A., and H. L. Weiner 1989. MS: a CNS and systemic autoimmune disease. Immunol. Today 10:104.
6. Lassmann, H. 1999. The pathology of multiple sclerosis and its evolution. Philos. Trans. R. Soc. London B 354:1635.
7. Panitch, H. S. 1995. Early treatment trials with interferon γ in multiple sclerosis. Mult. Scler. 1(Suppl. 1):S17.
8. Giovannoni, G., and D. H. Miller. 1999. Multiple sclerosis and its treatment. J. R. Coll. Physicians London 33:315.
9. Kato, T., M. Kitaura, K. Inaba, Y. Watanabe, Y. Kawade, and S. Muramatsu. 1992. Suppression of macrophage Ia antigen expression by endogenous interferon-α/β. J. Interferon Res. Spec. No. 29:41.
10. Li, Q., R. Milo, H. Panitch, and C. T. Bever, Jr. 1998. Effect of propranolol and IFN-β on the induction of MHC class II expression and cytokine production by IFN-γ IN THP-1 human monocytic cells. Immunopharmacol. Immunotoxicol. 20:39.
11. Noronha, A., A. Toscas, and M. A. Jensen. 1993. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J. Neuroimmunol. 46:145.
12. Rep, M. H., R. Q. Hintzen, C. H. Polman, and R. A. van Lier. 1996. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67:111.
13. Francis, G., F. Weber, and P. Rieckmann. 2000. Effect of interferon β on human myelin basic protein-specific T-cell lines: comparison of IFNβ-1a and IFNβ-1b. Neurology 55:322.
14. Lou, J., Y. Gasche, L. Zheng, C. Giroud, P. Morel, J. Clements, A. Ythier, and G. E. Grau. 1999. Interferon-β inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab. Invest. 79:1015.
15. Stuve, O., S. Chabot, S. S. Jung, G. Williams, and V. W. Yong. 1997. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon β-1b through an effect on matrix metalloproteinase-9. J. Neuroimmunol. 80:38.
16. Uhm, J. H., N. P. Dooley, O. Stuve, G. S. Francis, P. Duquette, J. P. Antel, and V. W. Yong. 1999. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon β-1b therapy. Ann. Neurol. 46:319.
17. McRae, B. L., R. T. Semnani, M. P. Hayes, and G. A. van Seventer. 1998. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160:4298.
18. Wang, X., M. Chen, K. P. Wandinger, G. Williams, and S. Dhib-Jalbut. 2000. IFN-β-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-β-1b therapeutic effects in multiple sclerosis. J. Immunol. 165:548.
19. Tuohy, V. K., M. Yu, L. Yin, P. M. Mathisen, J. M. Johnson, and J. A. Kawczak. 2000. Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J. Neuroimmunol. 111:55.
20. Erlandsson, L., R. Blumenthal, M. L. Eloranta, H. Engel, G. Alm, S. Weiss, and T. Leanderson. 1998. Interferon-β is required for interferon-α production in mouse fibroblasts. Curr. Biol. 8:223.
21. Sing, A., T. Merlin, H. P. Knopf, P. J. Nielsen, H. Loppnow, C. Galanos, and M. A. Freudenberg. 2000. Bacterial induction of β interferon in mice is a function of the lipopolysaccharide component. Infect. Immun. 68:1600.
22. Heinzelmann, M., M. A. Mercer-Jones, S. A. Gardner, M. A. Wilson, and H. C. Polk. 1997. Bacterial cell wall products increase monocyte HLA-DR and ICAM-1 without affecting lymphocyte CD18 expression. Cell. Immunol. 176:127.
23. Rubel, C., P. Miliani De Marval, M. Vermeulen, M. A. Isturiz, and M. S. Palermo. 1999. Lipopolysaccharide enhances FcγR-dependent functions in vivo through CD11b/CD18 up-regulation. Immunology 97:429.
24. Pette, M., D. F. Pette, P. A. Muraro, E. Farnon, R. Martin, and H. F. McFarland. 1997. Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology 49:385.
25. Bartholome, E. J., F. Willems, A. Crusiaux, K. Thielemans, L. Schandene, and M. Goldman. 1999. Interferon-β inhibits Th1 responses at the dendritic cell level: relevance to multiple sclerosis. Acta Neurol. Belg. 99:44.
26. Kozovska, M. E., J. Hong, Y. C. Zang, S. Li, V. M., Rivera, J. M. Killian, and J. Z. Zhang. 1999. Interferon β induces T-helper 2 immune deviation in MS. Neurology 53:1692.
27. Calabresi, P. A., C. M. Pelfrey, L. R. Tranquill, H. Maloni, and H. F. McFarland. 1997. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon β. Neurology 49:1111.
28. Fujimura, M., Y. Gasche, Y. Morita-Fujimura, J. Massengale, M. Kawase, and P. H. Chan. 1999. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842:92.
29. Leppert, D., R. L. Lindberg, L. Kappos, and S. L. Leib. 2001. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev. 36:249.
30. Heinzelmann, M., H. C. Polk, Jr., A. Chernobelsky, T. P. Stites, and L. E. Gordon. 2000. Endotoxin and muramyl dipeptide modulate surface receptor expression on human mononuclear cells. Immunopharmacology 48:117.
31. Kallmann, B. A., V. Hummel, T. Lindenlaub, K. Ruprecht, K. V. Toyka, and P. Rieckmann. 2000. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 123:687.
32. Zeuke, S., A. J. Ulmer, S. Kusumoto, H. A. Katus, and H. Heine. 2002. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc. Res. 56:126.
33. 4/β1 integrin. Nature 356:63.
34. 4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. USA 96:6896.
35. 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58:1.
36. Sadler, R. H., M. A. Sommer, L. S. Forno, and M. E. Smith. 1991. Induction of anti-myelin antibodies in EAE and their possible role in demyelination. J. Neurosci. Res 30:616.
37. Adelmann, M., J. Wood, I. Benzel, P. Fiori, H. Lassmann, J. M. Matthieu, M. V. Gardinier, K. Dornmair, and C. Linington. 1995. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J. Neuroimmunol. 63:17.
38. Iglesias, A., J. Bauer, T. Litzenburger, A. Schubart, and C. Linington. 2001. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36:220.
39. Vasconcellos, R., D. Braun, A. Coutinho, and J. Demengeot. 1999. Type I IFN sets the stringency of B cell repertoire selection in the bone marrow. Int. Immunol. 11:279.
40. Biswas, S. K., and A. Sodhi. 2002. In vitro activation of murine peritoneal macrophages by monocyte chemoattractant protein-1: upregulation of CD11b, production of proinflammatory cytokines, and the signal transduction pathway. J. Interferon Cytokine Res. 22:527.
41. 2 (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1. J. Biol. Chem. 277:19001.
42. Berton, G., and C. A. Lowell. 1999. Integrin signalling in neutrophils and macrophages. Cell. Signalling 11:621.
43. Fan, S. T., and T. S. Edgington. 1993. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-α responses of monocytes. J. Immunol. 150:2972.
44. Lecoanet-Henchoz, S., J. F. Gauchat, J. P. Aubry, P. Graber, P. Life, N. Paul-Eugene, B. Ferrua, A. L. Corbi, B. Dugas, C. Plater-Zyberk, et al. 1995. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity 3:119.
45. Aubry, J. P., N. Dugas, S. Lecoanet-Henchoz, F. Ouaaz, H. Zhao, J. F. Delfraissy, P. Graber, J. P. Kolb, B. Dugas, and J. Y. Bonnefoy. 1997. The 25-kDa soluble CD23 activates type III constitutive nitric oxide-synthase activity via CD11b and CD11c expressed by human monocytes. J. Immunol. 159:614.
46. 2 integrin by antibodies or soluble CD23 induces IL-1β production on primary human monocytes through mitogen-activated protein kinase-dependent pathways. Blood 95:3868.
47. van der Laan, L. J., S. R. Ruuls, K. S. Weber, I. J. Lodder, E. A. Dopp, and C. D. Dijkstra. 1996. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-α and nitric oxide. J. Neuroimmunol. 70:145.
48. Huitinga, I., J. G. Damoiseaux, E. A. Dopp, and C. D. Dijkstra. 1993. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:709.
49. Juedes, A. E., and N. H. Ruddle. 2001. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J. Immunol. 166:5168.
50. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193.
51. Klinkert, W. E., K. Kojima, W. Lesslauer, W. Rinner, H. Lassmann, and H. Wekerle. 1997. TNF-α receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview. J. Neuroimmunol. 72:163.
52. Huitinga, I., N. van Rooijen, C. J. de Groot, B. M. Uitdehaag, and C. D. Dijkstra. 1990. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172:1025.
53. Cleveland, M. G., R. B. Ramirez, and G. R. Klimpel. 1988. IFN-β production by macrophages obtained from mice undergoing graft vs host disease. J. Immunol. 141:3823.